Rituximab in severe, treatment-refractory interstitial lung disease

Respirology

Volumn 19, Issue 3, 2014, Pages 353-359

  Keir, Gregory J ^a,b   Maher, Toby M ^a   Ming, Damien ^a   Abdullah, Reza ^a,c   De Lauretis, Angelo ^d   Wickremasinghe, M ^b   Nicholson, Andrew G ^a   Hansell, David M ^a   Wells, Athol U ^a   Renzoni, Elisabetta A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d CARLO POMA HOSPITAL   (Italy)

Author keywords

interstitial lung disease; rescue therapy; rituximab; treatment

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; CLINICAL ASSESSMENT; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG FATALITY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; AGED; LUNG; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896314589     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12214     Document Type: Article

References (35)

1. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54: 3962-3970.
2. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, et al. (Scleroderma Lung Study Research Group). Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 22: 2655-2666.
3. Selman M, Buendía-Roldán I,. Immunopathology, diagnosis, and management of hypersensitivity pneumonitis. Semin. Respir. Crit. Care Med. 2012; 33: 543-554.
4. Corte TJ, Ellis R, Renzoni EA, Hansell DM, Nicholson AG, du Bois RM, Wells AU,. Use of intravenous cyclophosphamide in known or suspected advanced non-specific interstitial pneumonia. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26: 132-138.
5. Sem M, Molberg O, Lund MB, Gran JT,. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48: 968-971.
6. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP,. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-280.
7. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA,. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur. Respir. J. 2012; 40: 641-648.
8. Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA,. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 2013; 68: 780-781.
9. Perosa F, Prete M, Racanelli V, Dammacco F,. CD-20 depleting therapy in autoimmune disease: from basic research to the clinic. J. Intern. Med. 2010; 267: 260-277.
10. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 613-620.
11. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T,. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350: 2572-2581.
12. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, et al. (DANCER Study Group). The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54: 1390-1400.
13. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, et al. (REFLEX Trial Group). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54: 2793-2806.
14. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, et al. (European Vasculitis Study Group). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363: 211-220.
15. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, et al. (RAVE-ITN Research Group). Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363: 221-232.
16. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG,. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 2007; 146: 25-44.
17. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (Suppl. 5): v1-58.
18. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23: 581-590.
19. Alarcon-Segovia D, Cardiel MH,. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J. Rheumatol. 1989; 16: 328-334.
20. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 1975; 292: 344-347.
21. Mosca M, Neri R, Bombardieri S,. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin. Exp. Rheumatol. 1999; 17: 615-620.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-324.
23. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
24. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al.; European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002; 61: 554-558.
25. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P,. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71: 301-326.
26. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU,. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-537.
27. Youinou P, Hillion S, Jamin C, Pers JO, Saraux A, Renaudineau Y,. B lymphocytes on the front line of autoimmunity. Autoimmun. Rev. 2006; 5: 215-221.
28. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S,. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
29. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-762.
30. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I,. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosis after B cell depletion therapy. Arthritis Rheum. 2007; 56: 3044-3056.
31. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP,. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin. Exp. Rheumatol. 2012; 30: S17-S22.
32. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV,. Interstitial lung disease in idiopathic inflammatory myopathy. Curr. Rheumatol. Rev. 2010; 6: 108-119.
33. Churg A, Sin DD, Everett D, Brown K, Cool C,. Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am. J. Surg. Pathol. 2009; 33: 1765-1770.
34. Walsh SL, Sverzellati N, Devaraj A, Wells AU, Hansell DM,. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur. Radiol. 2012; 22: 1672-1679.
35. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB,. Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 2013; 72: 1496-1502.